Диссертация (Клинико-фармакологические подходы к персонализации назначения препаратов метаболического ряда при лечении пациентов с ишемической болезнью сердца), страница 50

Sackett, R. Hayness, M. Gent [et al.] //Monitoring for drug safety / ed. by W. Inman. – 2nd ed. – Lancaster, England, 1986. –P. 471-483.266. D’Andrea, G. A polymorphism in the VKORC1 gene is associated withan interindividual variability in the dose-anticoagulant effect of warfarin [Text] / G.D’Andrea, R.L. D’Ambrosio, P. Di Perna et al.// Blood.

– 2005. – V.105. – P.645649.267. Davidovits, P. Photomicrography of corneal endothelial cells in vivo[Text] /P. Davidovits, M.D. Egger // Nature. – 1973. – V. 244– P. 366-367.335268.Depre, C. Metabolic aspects of programmed cell survival and cell deathin the heart [Text] /C. Depre, H. Taegtmeyer// Cardiovasc. Res. – 2000. – V.45. –P.538-548.269.Detry, J. Trimetazidine: a new concept in the treatment of anginacomparison with propranolol in patients with stable angina [Text] /J. Detry, P. Sellier// Br. J.

Clin. Pharmacol. – 1994. – V.37. – P.279-288.270.Dietz, M.C. New therapeutic approaches to mendelian disorders [Text]/M.C. Dietz // N. Engl. J. Med. – 2010. – V.363, №9. – P.852-883.271.Doolittle, M. H. Lipase and phospholipase protocols [Text] / M. H.Doolittle, K. Reue. - Humana Press, 1999. – 109 p.272.Effect of 48-h intravenous trimetazidine on short- and long-termoutcomes of patients with acute myocardial infarction, with and without thrombolytictherapy ; a double-blind, placebo-controlled, randomized trial.

The EMIP-FR Group.European Myocardial Infarction Project – Free Radicals [Text] // Eur. Heart J. – 2000.– Vol. 21, № 18. – P. 1537-1546.273.Egger, M.D. New reflected-light microscope for viewing unstained brainand ganglion cells [Text] / M.D.

Egger, M. Petran // Science. – 1967. – V. 157. –305—307.274. Empana, J.P. PRIME Study Group. Contributions of depressive moodand circulating inflammatory markers to coronary heart disease in healthy Europeanmen: the Prospective Epidemiological Study of Myocardial Infarction (PRIME)[Text] /J.P. Empana, D.H. Sykes, G.

Luc et al. // Circulation. – 2005. – V.111. –P.2299-2305.275. Ferrary, R. Metabolic disturbances during myocardial ischemia andreperfusion [Text] /R. Ferrary // Am. J. Cardiol. – 1995. – V.76. – P.17B-24B.336276.Ford, E.S. Changes in prevalence of nonfatal coronary heart disease inthe United States from 1971-1994 [Text] /E.S. Ford, W.H.

Giles //Ethn. Dis. - 2003. –V.13. – P.85-93.277. Friedman, M. Effect of discontinuance of tape A behavioral counselingon tape A behavior and cardiac recurrence rate of post myocardial infarction patients[Text] /M. Friedman, L.H. Powell, C.E. Thoresen et al. // Am. Heart J.

– 1987. –V.114. – P.483-490.278. Fukuchi, M. Heterogeneous expression and activity of endothelial andinducible nitric oxide synthases in end-stage human heart failure. Their relation tolesion site and β-adrenergic receptor therapy [Text] /M. Fukuchi, S.N.A. Hussain, A.Giaid //Circulation. – 1998. – V.98. – P.132-139.279.Functional arrays for high throughput characterization of geneexpression regulatory elements [Text] : pat.

US 20070161031 A1 : Int. Cl. C40B 3006, C40B 40/02, C40B 50/06 ; US. Cl. 435/6 435/325 / N. D. Trinklein, RedwoodCity CA, S. F. Aldred, Hayward CA, S. J. Cooper, Seattle WA [et al.]. – № US11/636,385 ; appl. 07.12.2006 ; publ. 12.07.2007.

– 38 p.280.Gairola, C.G. Dietary coenzyme Q10 does not protect against cigarettesmoke-augmented atherosclerosis in apoE-deficient mice [Text] / C.G. Gairola, D.A.Howan, A. Daugherty // Free Rad. Biol. Med. – 2010. – Vol.48. – P.1535-1539.281. Gallo, M.P. Regulation of cardiac calcium current by NO and cGMPmodulating agents [Text] / M.P.

Gallo, D. Malan, I.Bedendi et al.// Pflugers Arch. –2001. – V.441. – P.621-628.282.Genini, D. Deoxyadenosine analogs induce programmed cell death inchronic lymphocytic leukemia cells by damaging the DNA and by directly affectingthe mitochondria [Text] / D. Genini, S. Adachi, Qi Chao et al. / Blood. – 2000. – V.96. – № 10. – P. 3537– 3543.337283.Genom-based personalized medicine [Text] : pat. US 2002/0115073 A1: Int. Cl.7 C12Q 1/68, C12N 15/02 ; US. Cl. 435/6, 435/449 / N. Papadopoulos,Brookline MA, Hai Yan, Baltimore MD, B.

Vogelstein, Baltimore MD [et al.]. – №09/784,305 ; appl. 16.02.2001 ; publ. 22.08.2002. – 11 p.284. Gerr, H. Acute leukaemias of ambiguous lineage in children:characterization, prognosis and therapy recommendations [Text] / H. Gerr, M.Zimmermann, M. Schrappe et al. // Br. J. Haematol. – 2010. – V.149. – P.84-92.285. Geronikaki, A.A. Computer-aided discovery of anti-inflammatorythiazolidinones with dual cyclooxygenase/ lipoxygenase inhibition [Text] / A.A.Geronikaki, A.A. Lagunin, D.I. Hadjipavlou-Litina et al. // J. Med. Chem. – 2008. –V.51. – №6.

– P.1601-1609.286.Gonzalez, S. Changing paradigms in dermatology: confocal microscopyin clinical and surgical dermatology [Text] /S. Gonzalez, K. Swindells,M.Rajadhyaksha, A. Torres// Clin. Derm. – 2003. –V. 21. –P. 359—369.287. Gorman, J.M., Sloan R.P. Heart rate variability in depressive and anxierydisorders [Text] /J.M. Gorman, R.P. Sloan // Am. Heart J. – 2000. – Vol.140. –P.S77-83.288.Guidelines on the management of stable angina pectoris: executivesummary : the task force on the management of stable angina pectoris of the EuropeanSociety of Cardiology [Text] / G.

Montalescot, U. Sechtem, S. Achenbach [et al.] //Eur. Heart J. – 2013. – Vol.34. – P. 2949-3003.289. Hamilton, D.K. Scanning optical microscopy by objective lens [Text] /D.K. Hamilton, T. Wilson // Scanning, Journal of Physics E: Scientific Instruments. –1986. – V.19. – P. 52—54.290. Harpey, C. Trimetazidine, a cellular anti-ischemic agent [Text] /C.Harpey, P. Clauser, C. Labrid et al. // Cardiovasc. Drug Rev. – 1989. – V.6. – P.292312.338291. Hearse, D.J. Oxygen deprivation and early myocardial contractile failure:a reassessment of the possible role of adenosine triphosphate [Text] / D.J. Hearse //Am.

J. Cardiol. – 1979. – V.44. – P.1115-1121.292.Hintsa, T. Divergent influence of different type A dimensions on jobstrain and effort-reward imbalance [Text] /T. Hintsa, M. Hitsanen, M. Jokela et al.// J.Occup. Environ. Med. – 2010. – V.52. – P.1-7.293. Ho, P.M. Risk of adverse outcomes associated with concomitant use ofclopidogrel and proton pump inhibitors following acute coronary syndrome [Text]/P.M. Ho, T.M.

Maddox, L. Wang et al. // JAMA. – 2009. – V.301. – P.937-944.294.Hoskins,J.M.UGT1A1*28genotypeandirinotecan-inducedneutropenia: dose matters [Text] / J.M. Hoskins, R.M. Goldberg, P. Qu et al. // J. Natl.Cancer Inst. – 2007. – V.99. – P.1290-1295.295.Innocenti, F. Pharmacogenomics: Methods and Protocols (Methods inMolecular Biology) [Text] /F. Innocenti. - Human Press, 2005.

– 224p.296. Kantor, P.F. The antianginal drug trimetezidin shifts cardiac energymetabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondriallong-chain 3-ketoacyl coenzyme A thiolase [Text] /P.F. Kantor, A. Lucein, R. Kozak,G.D. Lopaschuk // Circ. Res. – 2000. – V.86. – P.580-588.297.

Kay, L. Improvement of long term preservation of the isolated arrestedrat heart by trimetazidine effects on energy state and mitochondrial function [Text] /L. Kay, C. Finelly, J. Aussedat et al. // Am. J. Cardiol. – 1995. – V.76. – P.45B-49B.298.Kirchheiner,J.CYP2D6andCYP2С19genotype-baseddoserecommendations for antidepressants: a first step towards subpopulation-specificdosages [Text] / J. Kirchheiner, K. Brosen, M.L. Dahl et al. // Acta. Psychiatr. Scand.– 2001. – V.104.

– P.173-192.339299.Kirchheiner, J. Pharmacogenetics in psychiatry – a useful clinical tool orwishful thinking for the future? [Text] / J. Kirchheiner, A. Seeringer, R. Viviani //Curr. Pharm. Des. – 2010. – V.16. – P.136-144.300. Klein, T.E. Estimation of the warfarin dose with clinical andpharmacogenetic data [Text] / T.E. Klein, R.B. Altman, N. Eriksson et al. // N. Engl.J.

Med. – 2009. – V.360. – P.753-764.301. Klusa, V. Mildronate and its neuroregulatory mechanisms: targeting themitochondria, neuroinflammation, and protein expression [Text] / V. Klusa, U.Beitnere, J. Pupuresajevs et al. //.. Medicina (Kaunas). – 2013. – Vol. 49(7). – P.301309.302.Kop, W.J. Chronic and acute psychological risk factors for clinicalmanifestations of coronary artery disease [Text] /W.J. Kop// Psychosom. Med. –1999. – V.61. – P.476-487.303. Labrou, A. Trimetazidine administration minimizes myocardial damageand improves left ventricular function after percutaneous coronary intervention [Text]/A. Labrou, G.

Giannoglou, D. Ziotas et al.// Am. J. Cardiovasc. Drugs. – 2007. –Vol.7. – P.143-150.304. Lagunin, A.A. Computer-aided selection of potential antihypertensivecompounds with dual mechanisms of action [Text] / A.A. Lagunin, O.A. Gomazkov,D.A. Filimonov et al.// J. Med. Chem. – 2003. – V.46. - №15. – P.3326-3332.305.Laika, B.

Intermediate metabolizer: increased side effects inpsychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6screening? [Text] /B. Laika, S. Leucht, S. Heres, W. Steimer // Pharmacogenomics J.– 2009. – V.9. – P.395-403.306. Lee, L. Metabolic manipulation in ischemic heart disease, a novelapproach to treatment [Text] / L.

Lee, J. Horowitz, M. Frenneaux //Eur. Heart J. –2004. – V.25. – P.634-641.340307.Lesperance, F. The association between major depression and levels ofsoluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein inpatients with recent acute coronary syndromes [Text] /F. Lesperance, N. FrasureSmith, P. Theroux, M. Irwin //Am. J. Psychiatr. – 2004.